Document zzjG73Q1ObKvr61mpo979jGx3
SUMMARY OF EFFECTIVENESS (Philadelphia Ordinance on Lead Paint)
The Philadelphia ordinance on childhood lead poisoning has been found to be the most effective ordinance now in existence for the following reasons:
A. It contains labeling provisions which should be in commom practice throughout the country.
B. It prohibits application of lead paint to toys, furniture or interiors of dwellings, and prohibits the sale or transfer of toys and furniture which are coated with lead paint.
C. It requires that where old lead paint is a hazardous condition,
it must be removed, not just painted over.
~
D. It provides for penalties should a violation be discovered.
'
E. It does not restrict the use of lead paint where it is necessary for exterior corrosion protection and where it is not recognized as harmful.
N11966
EFFECTIVENESS OF PHILADELPHIA FAINT ORDINANCE
(Reported by Hill & Knowlton)
^
Thomas Connor, sanitarian, accident control section of the Philadelphia Department of Public Health, regarding the effec tiveness of the Philadelphia paint ordinance passed in 1966, made the following points about the situation there:
1. From a compliance of the law standpoint (after the owner has been approached following a reported case), the law has been over 80 percent effective. The reason why it has not been
'100 percent effective is .the result of an inadequacy in the Philadelphia court system which has new been corrected.
2. They are very satisfied with the ordinance. There are two difficulties: 1) When a child comes down with a case of plumbism.. the family has often moved before paint samples can be taken; 2} The Health Department cannot inspect a property.- without being invited, unless they have a reported case. The housing department does some inspection.
3. Following are some figures on, effectiveness:
Year
Confirmed Cases
Fatalities
1950-1955 (no program) 1961 (E5B blood tests)
53 109
15 12
Ordinance Instituted in 1966
1968
184
1*
* This fatality may have resulted from a v/rong diagnosis of symptoms.
LIA-75691